Aduro Biotech (ADRO) Tops Q3 EPS Views; Receives EMA Orphan Drug Designation for CRS-207

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/13/2026

1. CSCO
2. CBRS
3. COHR
4. SPY
5. WYFI
6. STUB
7. EAT
8. BTGO
9. NVDA
10. GO

Go back to Aduro Biotech (ADRO) Tops Q3 EPS Views; Receives EMA Orphan Drug Designation for CRS-207

'Don't Panic' on Aduro Biotech (ADRO) Listeriosis Disclosure, Leerink Partners Says

November 24, 2015 10:43 AM EST

Leerink Partners analyst Seamus Fernandez is telling Aduro Biotech (NASDAQ: ADRO) shareholders not to panic, with shares down 14% following a single case of investigator assessed 'listeriosis' reported in ADRO's 10-Q filing.

"A single case of investigator assessed 'listeriosis' reported in ADRO's 10-Q filing... More